

## GP Pharm Therapeutic and Overview Pipeline Review H2

*GP Pharm Treatment Pipeline Review H2* 2016

PUNE, INDIA, November 14, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by GP Pharm, S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of



the therapeutics, its complete research and development history and the dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740540-gp-pharm-s-a-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the pipeline therapeutic landscape of GP Pharm, S.A.
- The report provides overview of GP Pharm, S.A. including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report assesses GP Pharm, S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GP Pharm, S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

## Reasons to buy

- Evaluate GP Pharm, S.A.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GP Pharm, S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GP Pharm, S.A.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

**Table of Contents** 

Table of Contents 2

List of Tables 3

List of Figures 3

GP Pharm, S.A. Snapshot 4

GP Pharm, S.A. Overview 4

Key Facts 4

GP Pharm, S.A. - Research and Development Overview 5

Key Therapeutic Areas 5

GP Pharm, S.A. - Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products - Monotherapy 8

GP Pharm, S.A. - Pipeline Products Glance 9

GP Pharm, S.A. - Early Stage Pipeline Products 9

Preclinical Products/Combination Treatment Modalities 9

GP Pharm, S.A. - Drug Profiles 10

leuprolide acetate - Drug Profile 10

**Product Description 10** 

Mechanism Of Action 10

**R&D Progress 10** 

octreotide acetate MAR - Drug Profile 11

**Product Description 11** 

Mechanism Of Action 11

**R&D Progress 11** 

Pegylated Doxorubicin - Drug Profile 12

**Product Description 12** 

Mechanism Of Action 12

R&D Progress 12

risperidone depot - Drug Profile 13

**Product Description 13** 

Mechanism Of Action 13

R&D Progress 13

GP Pharm, S.A. - Pipeline Analysis 14

GP Pharm, S.A. - Pipeline Products by Target 14

GP Pharm, S.A. - Pipeline Products by Route of Administration 15

GP Pharm, S.A. - Pipeline Products by Molecule Type 16

GP Pharm, S.A. - Pipeline Products by Mechanism of Action 17

GP Pharm, S.A. - Dormant Projects 18

GP Pharm, S.A. - Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 20

Appendix 21

Methodology 21

Coverage 21

Secondary Research 21

Access Report @ <a href="https://www.wiseguyreports.com/reports/740540-gp-pharm-s-a-product-pipeline-review-2016">https://www.wiseguyreports.com/reports/740540-gp-pharm-s-a-product-pipeline-review-2016</a>

Get in touch:

LinkedIn: <a href="https://twitter.com/company/4828928"><u>www.linkedin.com/company/4828928</u></a>
Twitter: <a href="https://twitter.com/WiseGuyReports"><u>https://twitter.com/WiseGuyReports</u></a>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: https://www.einpresswire.com/article/353796799

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.